Emory University
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Emory University sits in the top decile of US sponsors by registered trial count (#24 of 15,742 sponsors by registered trial count).
Emory University: 1,208 sponsored US clinical trials, 208 recruiting.
Emory University sponsors 1,208 registered US clinical trials on ClinicalTrials.gov, 208 of them currently recruiting, and 767 completed. 170 of these trials are in Phase 3-4 (later-stage) and 344 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Depression, with 12 trials.
Top-decile sponsor footprint
Emory University ranks in the top decile of sponsors by registered trial count (#24 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
767 of 926 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (82.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,208 total, page 16 of 25
The Reducing Disparities in Access to kidNey Transplantation (RaDIANT) Community Study
NCT02092727
A Study of Subcutaneous Bevacizumab in Relapsed / Progressive Glioblastoma
NCT02157103
Linagliptin Inpatient Trial
NCT02004366
Technology-supported Behavioral Feeding Intervention
NCT02119910
Evaluation of the Quality of Self-collected Blood Spot Specimens for Laboratory HIV Testing - An InvolveMENt Sub Study
NCT02043041
Bone Marrow Transplant With Abatacept for Non-Malignant Diseases
NCT01917708
Efficacy of Swedish Massage Therapy on Cancer-related Fatigue in Cancer Survivors
NCT01926678
Soy Isoflavone in Combination With Radiation Therapy and Cisplatin in SCC of the Head and Neck
NCT02075112
RCT of CBT for Insomnia With PLWHA
NCT02259101
Physical Conditioning and Decitabine for Newly Diagnosed AML Patients Age ≥ 60
NCT02234037
Evaluation of Magnetic Resonance Imaging (MRI) vs Molecular Breast Imaging (Tc-MBI) in Breast Cancer Patients
NCT02024074
Optimal Dose of Early Intervention to Prevent PTSD
NCT01959620
Comparison of Absorption of Vitamin D in Cystic Fibrosis
NCT01880346
Observational Study of HIV-associated Neurocognitive Disorder
NCT01966094
Dexamethasone Plus Virtual Reality Exposure Therapy for PTSD
NCT01965366
Immunosuppression in Amyotrophic Lateral Sclerosis (ALS)
NCT01884571
Mechanisms of Intradialytic Hypertension
NCT01947673
Fusion Targeted Biopsy of the Prostate
NCT02013414
Effects of PURPLE Cry Intervention
NCT02227979
Two Vitamin D Dosing Strategies in Children With Chronic Kidney Disease
NCT01909115
Intrathecal Hydromorphone for Labor Analgesia
NCT01598506
Optical Frequency Domain Imaging (OFDI) and Vascular Healing After Stent Placement
NCT01794949
African American Alzheimer's Progression Markers - CSF and Neuro-Imaging
NCT02089555
Effects of Treatment on Decision-making in Major Depression
NCT01916824
Dysport for the Treatment of OMD
NCT01921270
Capsulectomy vs Capsulotomy With Repair in Direct Anterior Total Hip Arthroplasty
NCT02121964
Stroke Gait Rehabilitation Using Functional Electrical Stimulation
NCT01668602
Sitagliptin Therapy in Hospitalized Patients With Type 2 Diabetes
NCT01845831
Cognitive AED Outcomes in Pediatric Localization Related Epilepsy (COPE)
NCT01891890
Study of Carfilzomib in Combination w/Dexamethasone in Patients w/Newly Diagnosed Multiple Myeloma
NCT01969565
Adjuvant Radiation for High Risk Bladder Cancer
NCT01954173
Exercise and Cognitive Retraining to Improve Cognition in Heart Failure.
NCT02151266
Right Ventricular Failure After Implantation of Left Ventricular Assist Devices
NCT01999712
Physiologic Effects of RBC Transfusion
NCT02566577
Pancreatic Insufficiency Secondary to Tobacco Exposure
NCT01988350
Changing Developmental Trajectories Through Early Treatment
NCT01985022
Omacetaxine for Consolidation and Maintenance
NCT01873495
Exparel vs. Standard Bupivicaine for Abdominoplasty
NCT01853176
Video-Based Education for Dermatology Patients on Systemic Corticosteroids
NCT01991236
Weekly Vitamin D in Pediatric IBD
NCT02076750
Oxytocin as Adjunctive Treatment of Schizophrenia
NCT01568528
D-cycloserine and Treatment of Feeding Disorders
NCT01923896
Immune Enhancement for Immunological Non-responders to ART
NCT01806870
Enoxaparin Dosing in Obesity
NCT01798550
Phase II Trial of Tivozanib in Advanced Hepatocellular Cancer
NCT01807156
Hydromorphone and C-section
NCT01598545
Innovative Web-Based Intervention for Smoking Cessation Among College Students
NCT01982825
DTI of the Brain and Cervical Spine: Evaluation in Normal Subjects and Patients With Cervical Spondylotic Myelopathy
NCT01868958
Evaluation of a Patient Navigation System to Reduce Time to Waitlisting for Potential Kidney Transplant Recipients
NCT01776073
Comparison of Behavioral Activation and Antidepressant Medication in the Treatment of Adolescents With Depression
NCT01740726
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 154 |
| Phase 2 | 190 |
| Phase 3 | 36 |
| Phase 4 | 134 |
Therapeutic Areas
What is open in the Emory University pipeline
208 recruiting of 1,208 indexed (17% open); 767 completed (63%).
Phase mix: 170 late (III/IV) vs 344 early (I/II) (early-phase heavy).
Top condition: Depression (12 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Emory University: open-pipeline peers nationwide
Peers matched on 1,208 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
Emory University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,208 trials (± recruiting share)
- Northwestern University · 1,209 trials · 15% recruiting
- University of Pittsburgh · 1,238 trials · 13% recruiting
- NYU Langone Health · 1,164 trials · 17% recruiting
- University of Alabama at Birmingham · 1,160 trials · 19% recruiting
Sponsors near 17% open enrollment (± trial volume)
- Baylor Research Institute · 17% recruiting · 180 trials
- National Institute on Alcohol Abuse and Alcoholism (NIAAA) · 17% recruiting · 93 trials
- Hunter College of City University of New York · 17% recruiting · 29 trials
- Ochsner Health System · 17% recruiting · 29 trials
Related
What to do with this Emory University page
1,208 registered trials is a research-attention snapshot, not an endorsement of Emory University or any single study.
- 208 of Emory University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Depression is the condition Emory University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Depression trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Emory University pipeline card: 1,208 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.